Syntegon Group, a leading strategic partner to the global pharmaceutical, biotech, and food industries, has reported a strong first half of 2025, marked by double-digit sales growth, significantly higher profitability, and robust cash flow.

Driven by the growth strategy launched in 2024, the company delivered sales of €824 million, an increase of 11 percent compared to the prior year, supported by particularly strong momentum in the Pharma segment.

EBITDA rose to €127 million, up 41 percent year-on-year, with margins expanding by 300 basis points to 15.5 percent. This performance reflects the contribution of all business units, higher volumes in high-margin projects, disciplined project execution, and faster-than-expected synergies from the Telstar acquisition. Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024. A book-to-bill ratio of 117 percent highlights the company’s strong order intake and provides a solid foundation for continued growth in the second half of the year.

“Our results for the first half of 2025 demonstrate the strength of our strategy and our ability to deliver consistently for our customers,” said Torsten Türling, CEO of Syntegon. “With strong top-line growth, margin improvements across all business units, and efficiency gains, Syntegon is well on track to achieve another record year.”

The Pharma segment continues to thrive, driven by rising demand in biologics and stricter regulatory requirements that support strong order intake for Syntegon’s aseptic, isolator-equipped Fill & Finish solutions. The Food segment also delivered significant margin expansion, reflecting the growing success of the new SVX product line and improved efficiencies across the business. While global trade uncertainties, such as U.S. tariffs, remain a potential headwind, Syntegon expects minimal impact thanks to its balanced global supply chain and strong partnerships with customers.

Eros Carletti, CFO of Syntegon, emphasized the financial progress: “In the first half of 2025, we achieved improvements across all key metrics. Our value creation program and disciplined execution are delivering sustainable cash flow and higher margins, laying a strong foundation for further investment and growth.”

Innovation remains a cornerstone of Syntegon’s success. At its flagship Pharmatag event in May, which welcomed a record 350 global pharma and biotech customers, the company unveiled SynTiso, a groundbreaking gloveless and highly autonomous RTU line solution for liquid pharmaceutical filling. Developed jointly with two customers, SynTiso is fully Annex 1 compliant and offers unmatched flexibility in drug dosage. The first customer delivery is expected in 2026, underlining Syntegon’s commitment to shaping the future of pharmaceutical manufacturing with cutting-edge technologies.

With a strong first half behind it, Syntegon is confident in sustaining its growth momentum and further expanding margins in 2025, reaffirming its position as a trusted lifecycle partner to the global Pharma, Biotech, and Food sectors.